Lee Charles Research was formed in 2024 by Private Label Distillery Owner, Paul Thomas Dunning.
Lee is Paul’s mother’s middle name & Charles his father’s middle name. Lee Charles Research mission is to end stage 2 cancers by 2045 through promising DNA fragment cancer testing.
At 44, Paul is fighting stage 4 colon cancer that developed in his mid 30s and he has decided to spend 50% of his remaining time developing cancer prevention, treatment and research (C-PTR).
Lee Charles will start offering Global AI Assisted Clinical Trial Monitoring (GAACTM) by December 31st 2024.
Roughly 18% of patients die from cancer when clinical trials are available simply because the patient does not know about the trial.
